System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Lars H Lindner is an expert in Oncology at LMU Klinikum (Germany). As of September 2026, ScienceLeadR ranks Lars H Lindner in the top 1% of experts worldwide for Sarcoma. Lars H Lindner has authored 237 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 3 of them ongoing. SLR score: 826 (community average: 125). How the SLR is computed.

LeadR Profile

Lars H Lindner LMU Klinikum Germany
826 ScienceLeadR Reputation 826

Unlock

Register Login
Network Map

Oncology

Subspecialties: Surgery - Medical Imaging - Histology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Ludwig-Maximilians-Universität München

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 237

Citations

Citations: 6 880 1st author: 20 Last author: 42 Unique author: 8

Main journals

J Clin Oncol 21
Cancers (Basel) 14
Int J Hyperthermia 12
J Control Release 10
Ann Oncol 9

Best Journals

J Clin Oncol 4
Lancet Oncol 3
Ann Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Variations in surgical strategies and treatment allocation for retroperitoneal sarcomas across German-speaking sarcoma centres.
PMID 42566937 — multiple chronic conditions, sarcoma, histology, therapeutics		Eur J Surg Oncol20260
Prognostic Factors and Survival Outcomes in Resectable Thoracic Soft Tissue and Bone Sarcomas.
PMID 42352438 — neoplasms, sarcoma, therapeutics, tissues, prognosis		Cancers (Basel)20261
Stereotactic heart ablative radiotherapy (SHARP): a prospective multicentric phase II trial.
PMID 41615458 — radiotherapy, heart, neoplasms, therapeutics		Strahlenther Onkol20260
Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort Study.
PMID 42247057 — cohort studies, machine learning, sarcoma, histology, therapeutics, learning, tissues		Oncol Ther20260
Response to Letter to the Editor: Comments on "Surgery for Retroperitoneal Soft Tissue is Safe following Multimodal Treatment with Regional Hyperthermia".
PMID 42084691 — hyperthermia, combined modality therapy, therapeutics, tissues		Ann Surg Oncol20260

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 7
Phase 2 3
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 6
Unknown 3
Recruiting 2
Active not recruiting 1

By type:

Interventional 12

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 2
multicentricup10 7

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Public Title Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First line Treatment in Participants with Metastatic Leiomyosarcoma
2022-502975-45-00 — leiomyosarcoma, doxorubicin, therapeutics		Phase 3Active not recruiting2023
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
2022-501180-40-00 — sarcoma, ewing, maintenance, sarcoma, therapeutics		Phase 3Recruiting2022
tTF NGR Randomized Study STS
NCT05597917 — safety, saline solution, aminopeptidases, neoplasms, disease progression, drug therapy, contraindications, sarcoma, trabectedin, therapeutics, tissues, cd13 antigens, chemotherapy		Phase 3Recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS